BioXcel Therapeutics Inc
BTAI
Get informed when a big investor buys or sells
+ FollowMarket Cap$27.84M
Close$
$-1.08
195.8% downside
Current Fair Value
195.8% downsideOvervalued by 195.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $27.84 Million |
|---|---|
| Enterprise Value | $119.45 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-5.73 |
| Beta | 0.27 |
| Outstanding Shares | 12,208,000 |
Return
| Return on Equity | 61.37% |
|---|---|
| Return on Assets | -246.05% |
| Return on Invested Capital | 52.36% |
Valuation & Multiples
| P/E Ratio | -0.13 |
|---|---|
| PEG | 0.58 |
| Price to Sales | - |
| Price to Book Ratio | -0.11 |
| Enterprise Value to Revenue | 160.99 |
| Enterprise Value to EBIT | -2.11 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.87 |
| Debt to Equity | -0.9 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$-0.44
Average shareholder expectationRevenue Estimate
$484,630
Average shareholder expectationNext Earnings Call
Expected Date
November 18, 2026
EPS Estimate
$-0.63
Average shareholder expectationRevenue Estimate
$445,697
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 44.57%▲ 15.60% |
|---|---|
| Total Invested | $7.28M▲ 28.45% |
| Investors Holding | 40▼ 1.00% |
ESG Score
No data
About BioXcel Therapeutics Inc
CEO: Vimal Mehta